Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study.
EDSS
Efficacy
Fingolimod
Multiple Sclerosis
Safety
Journal
Caspian journal of internal medicine
ISSN: 2008-6164
Titre abrégé: Caspian J Intern Med
Pays: Iran
ID NLM: 101523876
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
entrez:
5
7
2021
pubmed:
6
7
2021
medline:
6
7
2021
Statut:
ppublish
Résumé
Fingolimod was the first oral therapy approved for treating relapsing-remitting multiple sclerosis (RRMS) in 2010. This open-label study evaluated the safety and efficacy of fingolide A multicenter, open-label, longitudinal was designed to evaluate the safety and efficacy of fingolide A total of 252 patients with the mean treatment duration of 343±45.70 days were. 20 patients experienced adverse events (AEs) and serious adverse events (SAEs) such as resistant urinary tract infection (UTI), premature atrial contraction (PAC), skin allergic reaction, macular edema, chicken pox, zona, panic attacks, and exacerbations associated with steroids treatment, all of which led to Fingolide The obtained findings suggest that the administration of Fingolide
Sections du résumé
BACKGROUND
BACKGROUND
Fingolimod was the first oral therapy approved for treating relapsing-remitting multiple sclerosis (RRMS) in 2010. This open-label study evaluated the safety and efficacy of fingolide
METHODS
METHODS
A multicenter, open-label, longitudinal was designed to evaluate the safety and efficacy of fingolide
RESULTS
RESULTS
A total of 252 patients with the mean treatment duration of 343±45.70 days were. 20 patients experienced adverse events (AEs) and serious adverse events (SAEs) such as resistant urinary tract infection (UTI), premature atrial contraction (PAC), skin allergic reaction, macular edema, chicken pox, zona, panic attacks, and exacerbations associated with steroids treatment, all of which led to Fingolide
CONCLUSION
CONCLUSIONS
The obtained findings suggest that the administration of Fingolide
Identifiants
pubmed: 34221275
doi: 10.22088/cjim.12.3.263
pmc: PMC8223042
doi:
Types de publication
Journal Article
Langues
eng
Pagination
263-274Informations de copyright
Copyright © 2020, Babol University of Medical Sciences.
Références
Clin Neuropharmacol. 2010 Mar-Apr;33(2):91-101
pubmed: 20061941
Neurology. 2015 Jun 9;84(23):2377-8
pubmed: 25957334
Mult Scler Int. 2015;2015:763418
pubmed: 26266049
N Engl J Med. 2010 Feb 4;362(5):402-15
pubmed: 20089954
Mult Scler. 2016 Jan;22(1):122-4
pubmed: 26219664
Neurology. 2014 Feb 25;82(8):674-80
pubmed: 24463630
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Neurosci Lett. 2017 Jul 13;653:258-263
pubmed: 28576565
Nat Rev Neurol. 2014 Mar;10(3):125
pubmed: 24514867
N Engl J Med. 2010 Feb 4;362(5):387-401
pubmed: 20089952
J Clin Pharmacol. 2015 Oct;55(10):1131-6
pubmed: 25903516
Mult Scler Relat Disord. 2018 May;22:22-26
pubmed: 29524758
Br J Clin Pharmacol. 2015 Sep;80(3):607-8
pubmed: 26077133
Mult Scler. 2015 Mar;21(3):342-9
pubmed: 25533301
J Postgrad Med. 2001 Jan-Mar;47(1):45-50
pubmed: 11590294
Mult Scler. 2016 Mar;22(3):389-92
pubmed: 26199353
J Neurol. 2014 Feb;261(2):267-76
pubmed: 24221641
Mult Scler Relat Disord. 2015 May;4(3):273-80
pubmed: 26008945
Ophthalmology. 2013 Jul;120(7):1432-9
pubmed: 23531349
Iran J Neurol. 2013;12(4):136-43
pubmed: 24250923
J Neuroimmunol. 2015 Dec 15;289:93-7
pubmed: 26616877
JAMA Neurol. 2015 Jan;72(1):31-9
pubmed: 25419615
Neurology. 2012 Feb 28;78(9):672-80
pubmed: 22371414
Mult Scler Relat Disord. 2020 Jul;42:102132
pubmed: 32387974
Iran J Neurol. 2018 Apr 4;17(2):64-70
pubmed: 30210730
Adv Ther. 2014 Oct;31(10):1072-81
pubmed: 25245812
Neurology. 2015 Jan 6;84(1):99-100
pubmed: 25416038
Mult Scler. 2016 Feb;22(2):201-11
pubmed: 26041795
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237
Lancet Neurol. 2014 Jun;13(6):545-56
pubmed: 24685276
PLoS One. 2015 Jul 06;10(7):e0132139
pubmed: 26147106
Neurosciences (Riyadh). 2018 Apr;23(2):129-134
pubmed: 29664454
Adv Ther. 2015 Jul;32(7):626-35
pubmed: 26170105
Eur Neurol. 2017;77(5-6):258-261
pubmed: 28359058
Mult Scler Relat Disord. 2019 Nov;36:101415
pubmed: 31586799
J Investig Med High Impact Case Rep. 2015 Mar 09;3(1):2324709615575551
pubmed: 26425635
PLoS One. 2016 Jan 06;11(1):e0146190
pubmed: 26734938
Clin Exp Dermatol. 2016 Jun;41(4):433-4
pubmed: 26577239
Mult Scler. 2015 Oct;21(11):1473-5
pubmed: 26283695
Neurology. 2015 Sep 15;85(11):1001-3
pubmed: 26291283